PURPOSE OF REVIEW:

During recent years different approaches have been explored to raise effective antitumor responses against brain tumors and particularly glioblastomas (GBMs). In most cases, cancer vaccines were based on autologous dendritic cells loaded with GBM peptides or whole tumor lysates. Many phase I-II studies showed that such strategy is feasible and nontoxic but failed to provide convincing evidence of its efficacy. This was due to study design and other biological issues: local immune suppression and insufficient characterization of appropriate epitopes appear as particularly relevant.

Artikel-Nr.: 24(6):641-7 | PubMed-ID: 22027543 | DOI: 10.1097/WCO.0b013e32834cbb17 | ISBN: